SUFOTIDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H31N5O3S
Molecular Weight	421.557
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1N=C(CS(C)(=O)=O)N=C1NCCCOC2=CC=CC(CN3CCCCC3)=C2

InChI

InChIKey=JEYKZWRXDALMNG-UHFFFAOYSA-N

InChI=1S/C20H31N5O3S/c1-24-20(22-19(23-24)16-29(2,26)27)21-10-7-13-28-18-9-6-8-17(14-18)15-25-11-4-3-5-12-25/h6,8-9,14H,3-5,7,10-13,15-16H2,1-2H3,(H,21,22,23)

HIDE SMILES / InChI

Molecular Formula	C20H31N5O3S
Molecular Weight	421.557
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1969833 | https://www.ncbi.nlm.nih.gov/pubmed/2574050 | https://www.ncbi.nlm.nih.gov/pubmed/1983344

Sufotidine is a triazolamine derivative patented by Glaxo Group Ltd. as long-acting histamine H2-blocker useful for the treatment of peptic ulceration and oesophagitis. In phase II clinical treatment with sufotidine decreases median integrated 24-hour intragastric acidity by 95% compared with placebo. Twice daily sufotidine maintained the pH above 3 throughout the 24 h. Unfortunately, no further development report has been published and it seems, that Sufotidine development currently discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

600 mg bd

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:36:57 GMT 2023` Edited by `admin` on `Fri Dec 15 15:36:57 GMT 2023`
Record UNII	56B0591Y76
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SUFOTIDINE

Official Name

English

AH-25352X

Code

English

sufotidine [INN]

Common Name

English

SUFOTIDINE [USAN]

Common Name

English

AH 25352X

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C29702